Wong Gary, Richardson Jason S, Pillet Stéphane, Racine Trina, Patel Ami, Soule Geoff, Ennis Jane, Turner Jeffrey, Qiu Xiangguo, Kobinger Gary P
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology.
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada.
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S379-83. doi: 10.1093/infdis/jiv102. Epub 2015 May 9.
Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.
埃博拉病毒（EBOV）可导致高达90%的EBOV感染人类死亡。在疫苗中，只有水泡性口炎病毒平台成功地在非人灵长类动物中提供了暴露后保护。在此，我们表明，一种佐剂化的人5型腺病毒（Ad5）载体疫苗（Ad5-扎伊尔埃博拉病毒糖蛋白）在埃博拉病毒攻击后30分钟和24小时分别接种时，保护了67%（9只中的6只）和25%（4只中的1只）的食蟹猕猴。该治疗在24小时给予时也保护了33%的恒河猴（3只中的1只）。这些结果突出了佐剂化Ad5疫苗在针对埃博拉病毒进行快速免疫方面的效用。
